Value Partners Group (HKG:0806), Insilico Medicine (HKG:3696), Shanghai Pudong Development Group, and Pudong Construction plan to jointly establish a RMB-denominated corporate venture capital fund.
The fund will focus on artificial intelligence and life sciences, according to a statement on Tuesday.
Value Partners' onshore private fund manager will serve as the fund's general partner and manager.
The parties plan to combine capital and industry resources to invest across the AI and life sciences ecosystem.